J. Hartlapp

772 total citations
48 papers, 483 citations indexed

About

J. Hartlapp is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, J. Hartlapp has authored 48 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in J. Hartlapp's work include Testicular diseases and treatments (11 papers), Cancer Treatment and Pharmacology (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). J. Hartlapp is often cited by papers focused on Testicular diseases and treatments (11 papers), Cancer Treatment and Pharmacology (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). J. Hartlapp collaborates with scholars based in Germany, United States and Switzerland. J. Hartlapp's co-authors include L. Weißbach, R Gugler, H. J. Illiger, D. Bach, R. Bußar-Maatz, W. Wagner, Rainer Krech, Bernhard Christoph, Michael Müller and Robert Michael Hermann and has published in prestigious journals such as The Journal of Urology, European Urology and European Journal of Cancer.

In The Last Decade

J. Hartlapp

46 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Hartlapp Germany 13 187 150 117 95 58 48 483
Robert D. Leeper United States 14 176 0.9× 161 1.1× 71 0.6× 148 1.6× 71 1.2× 22 962
W M Melia United Kingdom 17 299 1.6× 137 0.9× 112 1.0× 84 0.9× 145 2.5× 32 974
Daniel G. Miller United States 11 92 0.5× 220 1.5× 74 0.6× 129 1.4× 176 3.0× 23 661
De Haas Netherlands 9 170 0.9× 164 1.1× 68 0.6× 156 1.6× 59 1.0× 19 562
Vincent T. De Vita United States 9 64 0.3× 140 0.9× 154 1.3× 68 0.7× 178 3.1× 11 660
George Baumgartner United States 11 286 1.5× 79 0.5× 175 1.5× 61 0.6× 36 0.6× 38 472
Cheng‐Jueng Chen Taiwan 15 224 1.2× 109 0.7× 169 1.4× 249 2.6× 45 0.8× 45 722
Tomoya Shimokata Japan 18 109 0.6× 238 1.6× 330 2.8× 134 1.4× 70 1.2× 57 785
Fatih Köse Türkiye 13 143 0.8× 148 1.0× 161 1.4× 35 0.4× 48 0.8× 65 520
L Wahlqvist Sweden 17 554 3.0× 97 0.6× 344 2.9× 281 3.0× 26 0.4× 34 903

Countries citing papers authored by J. Hartlapp

Since Specialization
Citations

This map shows the geographic impact of J. Hartlapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Hartlapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Hartlapp more than expected).

Fields of papers citing papers by J. Hartlapp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Hartlapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Hartlapp. The network helps show where J. Hartlapp may publish in the future.

Co-authorship network of co-authors of J. Hartlapp

This figure shows the co-authorship network connecting the top 25 collaborators of J. Hartlapp. A scholar is included among the top collaborators of J. Hartlapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Hartlapp. J. Hartlapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hasan, Ibrahim, et al.. (2008). Palliative Behandlung des primären Leberzellkarzinoms mit Chemoembolisation. DMW - Deutsche Medizinische Wochenschrift. 117(15). 576–580.
2.
Scheuring, Urban, H. M. Seitz, Axel Wellmann, et al.. (2003). Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination. Medical Microbiology and Immunology. 192(4). 193–195. 16 indexed citations
3.
Hermann, Robert Michael, Rainer Krech, J. Hartlapp, et al.. (2001). Wertigkeit eines qualitativen Regressionsgradings als prognostischer Faktor für das Überleben bei präoperativ radiochemotherapierten Patienten mit fortgeschrittenen Kopf-Hals-Karzinomen. Strahlentherapie und Onkologie. 177(6). 277–282. 15 indexed citations
4.
Wagner, W., Robert Michael Hermann, J. Hartlapp, et al.. (2000). Prognostic Value of Hemoglobin Concentrations in Patients with Advanced Head and Neck Cancer Treated with Combined Radio-Chemotherapy and Surgery. Strahlentherapie und Onkologie. 176(2). 73–80. 27 indexed citations
5.
Horváth, Viktor J., J. Hartlapp, Susanna Hegewisch‐Becker, et al.. (2000). Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer. Oncology Research and Treatment. 23(4). 341–344. 7 indexed citations
6.
7.
Thürlimann, Beat, Nicolaus Kröger, K. Mross, et al.. (1995). Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of Cancer Research and Clinical Oncology. 121(S3). R3–R6. 10 indexed citations
8.
Heidemann, E., B. Steinke, J. Hartlapp, et al.. (1993). Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer. Oncology Research and Treatment. 16(5). 344–353. 10 indexed citations
9.
Bokemeyer, C., Hans‐Joachim Schmoll, A. Harstrick, et al.. (1993). A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. European Journal of Cancer. 29(16). 2225–2231. 21 indexed citations
10.
Beinlich, Ingo A., et al.. (1993). Pen-based remote data entry system. A pilot clinical trial.. PubMed. 43(3). 399–404. 5 indexed citations
11.
Steudel, A., et al.. (1992). Mangan-DPDP in der MR-Tomographie maligner Lebertumoren. Erste Ergebnisse mit einem neuen hepatobiliären Kontrastmittel. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 156(5). 460–464. 1 indexed citations
12.
Siewert, Bettina, et al.. (1992). MR-Venographie bei tiefen Bein- und Beckenvenenthrombosen. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 156(6). 549–554. 6 indexed citations
13.
Weißbach, L., et al.. (1989). Risk/Benefit of treating retroperitoneal teratoid bulky tumors. Urology. 34(1). 14–17. 7 indexed citations
14.
Hartlapp, J., et al.. (1989). Chemotherapy of a patient because of spuriously elevated alpha-fetoprotein levels. Journal of Molecular Medicine. 67(7). 408–412. 6 indexed citations
15.
Loos, U., et al.. (1988). The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma. European Journal of Clinical Pharmacology. 35(2). 187–193. 12 indexed citations
16.
Kersjes, W., et al.. (1988). Multiple Leberrundherde bei latenter Porphyria cutanea tarda. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 148(2). 165–168. 4 indexed citations
17.
Kleeberg, Ulrich R., et al.. (1987). Megestrolazetat versus Medroxyprogesteronazetat in der Behandlung metastasierender Mammakarzinome. Oncology Research and Treatment. 10(2). 104–106. 9 indexed citations
18.
Hartlapp, J.. (1987). Antimicrobial Prophylaxis in Immunocompromised Patients. Drugs. 34(Supplement 1). 131–133. 17 indexed citations
19.
Hartlapp, J., et al.. (1985). Alternatives to cyvadic-combination therapy of soft tissue sarcomas. Journal of Molecular Medicine. 63(22). 1160–1162. 5 indexed citations
20.
Schwabe, Holger, et al.. (1983). Flow-cytophotometric studies on urine sediments of patients treated with anti-cancer-drugs. Urological Research. 11(4). 159–62. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert D. Leeper Breakdown of academic impact, for papers by W M Melia Breakdown of academic impact, for papers by Daniel G. Miller Breakdown of academic impact, for papers by De Haas Breakdown of academic impact, for papers by Vincent T. De Vita Breakdown of academic impact, for papers by George Baumgartner Breakdown of academic impact, for papers by Cheng‐Jueng Chen Breakdown of academic impact, for papers by Tomoya Shimokata Breakdown of academic impact, for papers by Fatih Köse Breakdown of academic impact, for papers by L Wahlqvist
Rankless by CCL
2026